Comparison of six generic vancomycin products for treatment of methicillin-resistant staphylococcus aureus experimental endocarditis in rabbits

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1157-1162

  Tattevin, P ^a,b   Saleh Mghir, A ^c,d   Davido, B ^c   Ghout, I ^e   Massias, L ^f   Garcia De La Maria, C ^g   Miro J M ^g   Perronne, C ^c,d   Laurent, F ^h   Cremieux A C ^c,d  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d RAYMOND POINCARÉ HOSPITAL   (France)

^e HÔPITAL AMBROISE PARÉ   (France)

^f BICHAT HOSPITAL   (France)

^g UNIVERSITY OF BARCELONA   (Spain)

^h CROIX ROUSSE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BLOOD SAMPLING; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; ENDOCARDITIS; FRANCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPAIN; SWITZERLAND; TREATMENT DURATION; UNITED STATES;

ANIMALS; ANTI-BACTERIAL AGENTS; AORTIC VALVE; DRUGS, GENERIC; ENDOCARDITIS, BACTERIAL; HEART DEFECTS, CONGENITAL; HEART VALVE DISEASES; HUMANS; INJECTIONS, INTRAVENOUS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; RABBITS; STAPHYLOCOCCAL INFECTIONS; THERAPEUTIC EQUIVALENCY; VANCOMYCIN;

EID: 84874082322     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01669-12     Document Type: Article

References (29)

1. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak JM, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52: e18-e55. doi:10.1093/cid/ciq146.
2. Somerville AL, Wright DH, Rotschafer JC. 1999. Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease. Pharmacotherapy 19:702-707.
3. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson- Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide- Intermediate Staphylococcus aureus Working Group. N. Engl. J. Med. 340:493-501.
4. Sader HS, Fey PD, Limaye AP, Madinger N, Pankey G, Rahal J, Rybak MJ, Snydman DR, Steed LL, Waites K, Jones RN. 2009. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin- resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob. Agents Chemother. 53:4127- 4132.
5. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52: 3315-3320.
6. Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga AF. 2010. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob. Agents Chemother. 54:3271- 3279.
7. Rodriguez CA, Agudelo M, Zuluaga AF, Vesga O. 2012. Generic vancomycin enriches resistant subpopulations of Staphylococcus aureus after exposure in a neutropenic mouse thigh infection model. Antimicrob. Agents Chemother. 56:243-247.
8. Medscape-France. 2011. Antibiotiques génériques et princeps: sont-ils vraiment équivalents? http://www.medscape.fr/ infections-vaccins/articles/1279851/.
9. Gauzit R, Lakdhari M. 2012. Generic antibiotic drugs: is effectiveness guaranteed? Med. Mal. Infect. 42:141-148.
10. Crémieux AC, Carbon C. 1992. Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis. Antimicrob. Agents Chemother. 36:2069 -2074.
11. Tomasz A, Nachman S, Leaf H. 1991. Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci. Antimicrob. Agents Chemother. 35:124 -129.
12. Tattevin P, Basuino L, Bauer D, Diep BA, Chambers HF. 2010. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillinresistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54:610- 613.
13. R Development Core Team. 2011. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/.
14. Hothorn T, Bretz F, Westfall P. 2008. Simultaneous inference in general parametric models. Biom. J. 50:346 -363.
15. Chambers HF, Sande MA. 1984. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin- susceptible or -resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 26:61- 64.
16. Sande MA, Johnson ML. 1975. Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus. J. Infect. Dis. 131:367-375.
17. Crémieux AC, Maziere B, Vallois JM, Ottaviani M, Azancot A, Raffoul H, Bouvet A, Pocidalo JJ, Carbon C. 1989. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J. Infect. Dis. 159:938 -944.
18. Hadwiger ME, Sommers CD, Mans DJ, Patel V, and Boyne MT II. 2012. Quality assessment of U.S. marketplace vancomycin for injection products using high-resolution liquid chromatography-mass spectrometry and potency assays. Antimicrob. Agents Chemother. 56:2824 -2830.
19. Nambiar S, Madurawe RD, Zuk S, Khan SR, Ellison CD, Faustino PJ, Mans DJ, Trehy ML, Hadwiger ME, Boyne TM, Biswas K, Cox EM. 2012. Product quality of parenteral vancomycin products in the United States. Antimicrob. Agents Chemother. 56:2819 -2823.
20. Carbon C, Crémieux AC, Fantin B. 1993. Pharmacokinetic and pharmacodynamic aspects of therapy of experimental endocarditis. Infect. Dis. Clin. North Am. 7:37-51.
21. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111: e394-e434. doi:10.1161/CIRCULATIONAHA.105.165564.
22. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, Moreillon P, de Jesus Antunes M, Thilen U, Lekakis J, Lengyel M, Muller L, Naber CK, Nihoyannopoulos P, Moritz A, Zamorano JL. 2009. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009). The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur. Heart J. 30: 2369-2413.
23. Chiang FY, Climo M. 2003. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin- resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47:3002-3004.
24. Jacqueline C, Amador G, Batard E, Le Mabecque V, Miegeville AF, Biek D, Caillon J, Potel G. 2011. Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptideintermediate Staphylococcus aureus. J. Antimicrob. Chemother. 66:863- 866.
25. Geraci JE. 1977. Vancomycin. Mayo Clin. Proc. 52:631- 634.
26. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82-98.
27. Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, Brookhart MA, Avorn J, Shrank WH. 2010. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 70:605- 621.
28. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH. 2008. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 300:2514 -2526.
29. Zuluaga AF, Agudelo M, Cardeno JJ, Rodriguez CA, Vesga O. 2010. Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model. PLoS One 5:e10744. doi:10.1371/journal.pone.0010744.